Trevena (TRVN) 10-Q 12 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 10, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-36193
Entity Registrant Name	Trevena, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1469215
Entity Address, Address Line One	955 Chesterbrook Boulevard, Suite 110
Entity Address, City or Town	Chesterbrook
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	354-8840
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	TRVN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		164,508,838
Entity Central Index Key	0001429560
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 90,952	$ 109,403
Accounts receivable, net	137	71
Inventories	1,045
Insurance recovery	9,000	9,000
Prepaid expenses and other current assets	1,998	570
Total current assets	103,132	119,044
Restricted cash	1,310	1,310
Property and equipment, net	2,039	2,253
Right-of-use lease asset	4,921	5,119
Other assets	799	13
Total assets	112,201	127,739
Current liabilities:
Accounts payable, net	2,374	1,693
Accrued expenses and other current liabilities	2,852	5,168
Estimated settlement liability	9,000	9,000
Lease liability	748	703
Total current liabilities	14,974	16,564
Leases, net of current portion	6,718	7,101
Warrant liability	1	6
Total liabilities	21,693	23,671
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock-$0.001 par value; 200,000,000 shares authorized at June 30, 2021 and December 31, 2020; 164,508,838 and 159,999,917 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	165	160
Preferred stock-$0.001 par value; 5,000,000 shares authorized, none issued or outstanding at June 30, 2021 and December 31, 2020
Additional paid-in capital	556,721	546,422
Accumulated deficit	(466,378)	(442,514)
Total stockholders' equity	90,508	104,068
Total liabilities and stockholders' equity	$ 112,201	$ 127,739

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Balance Sheets
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock authorized (in shares)	200,000,000	200,000,000
Common stock issued (in shares)	164,508,838	159,999,917
Common stock outstanding (in shares)	164,508,838	159,999,917
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock authorized (in shares)	5,000,000	5,000,000
Preferred stock issued (in shares)	0	0
Preferred stock outstanding (in shares)	0	0

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Total revenue	$ 178		$ 387
Operating expenses:
Cost of goods sold	258		421
Selling, general and administrative	10,545	$ 3,300	17,913	$ 6,932
Research and development	3,449	2,958	6,085	5,149
Total operating expenses	14,252	6,258	24,419	12,081
Loss from operations	(14,074)	(6,258)	(24,032)	(12,081)
Other income (expense):
Change in fair value of warrant liability	2	(6)	5	(3)
Other income, net	7	26	76	95
Interest income	43	16	91	68
Interest expense				(29)
(Loss) gain on foreign currency exchange			(4)	3
Total other income	52	36	168	134
Net loss and comprehensive loss	$ (14,022)	$ (6,222)	$ (23,864)	$ (11,947)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.09)	$ (0.06)	$ (0.15)	$ (0.12)
Weighted average common shares outstanding, basic and diluted (in shares)	163,370,485	111,297,428	161,936,680	103,814,876
Product revenue
Revenue:
Total revenue	$ 178		$ 387

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2019	$ 94,000	$ 443,129,000	$ (413,145,000)	$ 30,078,000
Beginning Balance (in shares) at Dec. 31, 2019	94,213,760
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense		891,000		891,000
Issuance of common stock, net of issuance costs	$ 5,000	3,546,000		3,551,000
Issuance of common stock, net of issuance costs (in shares)	4,816,244
Net loss			(5,725,000)	(5,725,000)
Ending Balance at Mar. 31, 2020	$ 99,000	447,566,000	(418,870,000)	28,795,000
Ending Balance (in shares) at Mar. 31, 2020	99,030,004
Beginning Balance at Dec. 31, 2019	$ 94,000	443,129,000	(413,145,000)	30,078,000
Beginning Balance (in shares) at Dec. 31, 2019	94,213,760
Increase (Decrease) in Stockholders' Equity
Net loss				(11,947,000)
Ending Balance at Jun. 30, 2020	$ 127,000	480,293,000	(425,092,000)	55,328,000
Ending Balance (in shares) at Jun. 30, 2020	127,210,272
Beginning Balance at Mar. 31, 2020	$ 99,000	447,566,000	(418,870,000)	28,795,000
Beginning Balance (in shares) at Mar. 31, 2020	99,030,004
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense		766,000		766,000
Issuance of common stock, net of issuance costs	$ 28,000	32,001,000		32,029,000
Issuance of common stock, net of issuance costs (in shares)	28,135,057
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes		(40,000)		(40,000)
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares)	45,211
Net loss			(6,222,000)	(6,222,000)
Ending Balance at Jun. 30, 2020	$ 127,000	480,293,000	(425,092,000)	55,328,000
Ending Balance (in shares) at Jun. 30, 2020	127,210,272
Beginning Balance at Dec. 31, 2020	$ 160	546,422,000	(442,514,000)	$ 104,068,000
Beginning Balance (in shares) at Dec. 31, 2020	159,999,917			159,999,917
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense		1,111,000		$ 1,111,000
Exercise of stock options		9,000		9,000
Exercise of stock options (in shares)	5,000
Issuance of common stock, net of issuance costs	$ 1	2,791,000		2,792,000
Issuance of common stock, net of issuance costs (in shares)	1,219,023
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes		(69,000)		(69,000)
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares)	49,720
Net loss			(9,842,000)	(9,842,000)
Ending Balance at Mar. 31, 2021	$ 161	550,264,000	(452,356,000)	98,069,000
Ending Balance (in shares) at Mar. 31, 2021	161,273,660
Beginning Balance at Dec. 31, 2020	$ 160	546,422,000	(442,514,000)	$ 104,068,000
Beginning Balance (in shares) at Dec. 31, 2020	159,999,917			159,999,917
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)				137,184
Net loss				$ (23,864,000)
Ending Balance at Jun. 30, 2021	$ 165	556,721,000	(466,378,000)	$ 90,508,000
Ending Balance (in shares) at Jun. 30, 2021	164,508,838			164,508,838
Beginning Balance at Mar. 31, 2021	$ 161	550,264,000	(452,356,000)	$ 98,069,000
Beginning Balance (in shares) at Mar. 31, 2021	161,273,660
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense		1,182,000		1,182,000
Exercise of stock options	$ 1	170,000		171,000
Exercise of stock options (in shares)	132,184
Issuance of common stock, net of issuance costs	$ 3	5,153,000		5,156,000
Issuance of common stock, net of issuance costs (in shares)	3,058,879
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes		(48,000)		(48,000)
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares)	44,115
Net loss			(14,022,000)	(14,022,000)
Ending Balance at Jun. 30, 2021	$ 165	$ 556,721,000	$ (466,378,000)	$ 90,508,000
Ending Balance (in shares) at Jun. 30, 2021	164,508,838			164,508,838

Statement of Stockholders' Equi

Statement of Stockholders' Equity (Parenthetical) - $ / shares	Jun. 30, 2021	Jun. 30, 2020
Common stock, par value (in dollars per share)	$ 0.001
Common Stock
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities:
Net loss	$ (23,864)	$ (11,947)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	214	257
Stock-based compensation	2,293	1,657
Noncash interest expense on loans		8
Revaluation of warrant liability	(5)	3
Change in right-of-use asset	198	169
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets	(1,490)	(765)
Inventories	(1,045)
Operating lease liabilities	(334)	(293)
Accounts payable, accrued expenses and other liabilities	(1,635)	(628)
Net cash used in operating activities	(25,668)	(11,539)
Investing activities:
Long term deposits	(790)
Maturities of marketable securities		3,500
Net cash (used in) provided by investing activities	(790)	3,500
Financing activities:
Proceeds from exercise of common stock options	180
Proceeds from issuance of common stock, net	7,948	35,580
Payment of employee withholding taxes on vested restricted stock units	(117)
Finance lease payments	(4)	(5)
Repayments of loans payable, net		(5,045)
Net cash provided by financing activities	8,007	30,530
Net decrease in cash, cash equivalents and restricted cash	(18,451)	22,491
Cash, cash equivalents and restricted cash-beginning of period	110,713	33,614
Cash, cash equivalents and restricted cash-end of period	$ 92,262	56,105
Supplemental disclosure of cash flow information:
Cash paid for interest		$ 18

Organization and Description of

Organization and Description of the Business	6 Months Ended
	Jun. 30, 2021
Organization and Description of the Business
Organization and Description of the Business	1. Organization and Description of the Business Trevena, Inc., or the Company, was incorporated in Delaware as Parallax Therapeutics, Inc. in November 2007. The Company began operations in December 2007, and its name was changed to Trevena, Inc. in January 2008. The Company is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by central nervous system, or CNS, disorders. The Company operates in one segment and has its principal office in Chesterbrook, Pennsylvania. ​ Since commencing operations in 2007, the Company has devoted substantially all of its financial resources and efforts to commercializing its lead asset, OLINVYK® (oliceridine) injection, or OLINVYK, and to research and development, including nonclinical studies and clinical trials. The Company has never been profitable. In August 2020, the United States Food and Drug Administration, or FDA, approved the new drug application, or NDA, for OLINVYK. The Company initiated commercial launch of OLINVYK in the first quarter of 2021. ​ Since its inception, the Company has incurred losses and negative cash flows from operations. At June 30, 2021, the Company had an accumulated deficit of $466.4 million. The Company’s net loss was $23.9 million and $11.9 million for the six months ended June 30, 2021 and 2020, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements—Going Concern

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the ASC and Accounting Standards Update, or ASU, of FASB. The Company’s functional currency is the U.S. dollar. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s balance sheets as of June 30, 2021, its results of operations and its comprehensive loss for the three and six months ended June 30, 2021 and 2020, its statement of stockholders’ equity for the period from January 1, 2021 to June 30, 2021 and for the period January 1, 2020 to June 30, 2020, and its statements of cash flows for the six months ended June 30, 2021 and 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and accompanying notes included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2020. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies. The financial data and other information disclosed in these notes related to the six months ended June 30, 2021 and 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. We have been actively monitoring the novel coronavirus, or COVID-19, situation and its impact globally. Remote working arrangements and travel restrictions imposed by various jurisdictions have had a limited impact on our ability to maintain operations during the quarter. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, including vaccine adoption and effectiveness, the impact of emerging variants of the novel coronavirus, the actions taken to contain or treat COVID-19, including as a result of new information that may emerge concerning COVID-19. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. These estimates and assumptions are based on current facts, historical experience as well as other pertinent industry and regulatory authority information, including the potential future effects of COVID-19, the results of which form the basis for making judgements about the carrying values of assets and liabilities and the recording expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Fair Value of Financial Instruments Recently Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes ​ ​

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2021
Fair Value of Financial Instruments
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments ASC 820, Fair Value Measurement, ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: ● Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. ● Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. ● Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Cash, Cash Equivalents and Marketable Securities The following table presents fair value of the Company’s cash, cash equivalents, and marketable securities as of June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ Adjusted ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cash and Cash ​ Restricted ​ Marketable ​ ​ Cost Gains Losses Fair Value Equivalents Cash Securities Cash ​ $ 10,557 ​ $ — ​ $ — ​ $ 10,557 ​ $ 9,247 ​ $ 1,310 ​ $ — Level 1 (1): ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 81,705 ​ — ​ — ​ 81,705 ​ 81,705 ​ — ​ — Subtotal ​ 81,705 ​ — ​ — ​ 81,705 ​ 81,705 ​ — ​ — Total ​ $ 92,262 ​ $ — ​ $ — ​ $ 92,262 ​ $ 90,952 ​ $ 1,310 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ Adjusted ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cash and Cash ​ Restricted ​ Marketable ​ Cost Gains Losses Fair Value Equivalents Cash Securities Cash ​ $ 6,100 ​ $ — ​ $ — ​ $ 6,100 ​ $ 4,790 ​ $ 1,310 ​ $ — Level 1 (1): ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 104,613 ​ — ​ — ​ 104,613 ​ 104,613 ​ — ​ — Subtotal ​ 104,613 ​ — ​ — ​ 104,613 ​ 104,613 ​ — ​ — Total ​ $ 110,713 ​ $ — ​ $ — ​ $ 110,713 ​ $ 109,403 ​ $ 1,310 ​ $ — (1) The fair value of Level 1 securities is estimated based on quoted prices in active markets for identical assets or liabilities. The Company classifies investments available to fund current operations as current assets on its balance sheets. As of June 30, 2021, the Company did not hold any investment securities exceeding a one-year maturity. The Company maintains $1.3 million as collateral under a letter of credit for the Company’s facility lease obligations in Chesterbrook, Pennsylvania. The Company has recorded this deposit and accumulated interest thereon as restricted cash on its balance sheet. Unrealized gains and losses on marketable securities are recorded as a separate component of accumulated other comprehensive income (loss) included in stockholders’ equity. Realized gains (losses) are included in interest income (expense) in the statement of operations and comprehensive income (loss) on a specific identification basis. The Company did not record any realized gains or losses during the three and six months ended June 30, 2021 and 2020. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. Accretion of bond discount on marketable securities is included in other income as a separate component of other income (expense) on the statement of operations and comprehensive loss. Interest income on marketable securities is recorded as interest income on the statement of operations and comprehensive loss. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between Level 2 and Level 3 during the six months ended June 30, 2021, or the year ended December 31, 2020.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2021
Inventories, net
Inventories, net	4. Inventories, net Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Inventory includes the cost of API, raw materials and third-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are recorded as period costs in the period incurred. OLINVYK was approved by the FDA in August 2020. Prior to FDA approval, all manufacturing costs for OLINVYK were expensed to research and development. Upon FDA approval, manufacturing costs for OLINVYK manufactured for commercial sale have been capitalized as inventory cost. Costs of drug product to be consumed in any current or future clinical trials will continue to be recognized as research and development expense. The Company periodically evaluates the carrying value of inventory on hand using the same lower of cost or net realizable value approach as that used to initially value the inventory. Valuation adjustments may be required for slow-moving or obsolete inventory or in any situations where market conditions have caused net realizable value to fall below the carrying cost of the inventory.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity
Stockholders' Equity	5. Stockholders’ Equity Equity Offerings Under its certificate of incorporation, the Company was authorized to issue up to 200,000,000 shares of common stock as of June 30, 2021. The Company also was authorized to issue up to 5,000,000 shares of preferred stock as of June 30, 2021. The Company is required, at all times, to reserve and keep available out of its authorized but unissued shares of common stock sufficient shares to effect the conversion of the shares of the preferred stock and all outstanding stock options and warrants. ATM Programs In April 2019, the Company entered into a Common Stock Sales Agreement with H.C. Wainwright & Co., LLC, or Wainwright, pursuant to which the Company may offer and sell through Wainwright, from time to time at the Company’s sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the HCW ATM Program. Sales of the shares of common stock are deemed to be “at-the-market offerings,” as defined in Rule 415 under the Securities Act. In December 2020, the Company and Wainwright entered into Amendment No. 1 to Common Stock Sales Agreement, or the Amendment, to amend the Common Stock Sales Agreement to, among other things, update the reference to the registration statement pursuant to which the shares of common stock may be sold and to include an additional $50.0 million of shares of common stock in the HCW ATM Program. Between April 1, 2021 and May 10, 2021, the Company issued and sold approximately 3.1 million shares of common stock under the HCW ATM Program for net proceeds of approximately $5.2 million, after deducting related expenses, including commissions. There were no Registered Direct Offering and Concurrent Warrant Issuance ​ In January 2019, the Company entered into securities purchase agreements with two institutional investors wherein the Company agreed to sell to the investors an aggregate of 10,000,000 shares of its common stock, at an offering price of $1.00 per share, in a registered direct offering made pursuant to the Company’s existing registration statement on Form S-3. The net proceeds to the Company from the offering were $9.2 million, after deducting fees and the expenses of the placement agent. Pursuant to a letter agreement dated January 28, 2019, the Company engaged H.C. Wainwright & Co., LLC, or Wainwright, to act as its exclusive placement agent in connection with the issuance and sale of the shares. The Company paid Wainwright 7.0% of the aggregate gross proceeds in the offering and $50,000 for certain expenses, and it issued warrants to purchase 500,000 shares of common stock to certain designees of Wainwright. These warrants have a term of five years, are immediately exercisable and have an exercise price of $1.25 per share. During the year ended December 31, 2020, 327,500 of these warrants were exercised in a cashless exercise for 201,925 common shares. The warrants are classified as equity and were recorded at fair value as of the date of issuance on the Company’s Consolidated Balance Sheets and no further adjustments to their valuation are made. The letter agreement also includes indemnification obligations of the Company and other provisions customary for transactions of this nature. Equity Incentive Plans In 2008, the Company adopted the 2008 Equity Incentive Plan, as amended on February 29, 2008, January 7, 2010, July 8, 2010, December 10, 2010, June 23, 2011 and June 17, 2013, collectively, the 2008 Plan, that authorized the Company to grant restricted stock and stock options to eligible employees, directors and consultants to the Company. In 2013, the Company adopted the 2013 Equity Incentive Plan, as amended on May 14, 2014, collectively, 2013 Plan. The 2013 Plan became effective upon the Company’s entry into the underwriting agreement related to its IPO in January 2014 and, as of such date, no further grants were permitted under the 2008 Plan. The 2013 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company. Additionally, the 2013 Plan provides for the grant of cash and stock-based performance awards. The 2013 Plan contains an “evergreen” provision, pursuant to which the number of shares of common stock available for issuance under the plan automatically increases on January 1 of each year beginning in 2015. Under all such plans, the amount, terms of grants and exercisability provisions are determined by the board of directors or its designee. The term of the options may be up to 10 years, and options are exercisable in cash or as otherwise determined by the board of directors or its designee. Vesting generally occurs over a period of not greater than four years. For performance-based stock awards, the Company recognizes expense when achievement of the performance condition is probable, over the requisite service period. The estimated grant-date fair value of the Company’s stock-based awards is amortized on a straight-line basis over the awards’ service periods. Stock-based compensation expense recognized was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Research and development ​ $ 248 ​ $ 204 ​ $ 508 ​ $ 413 ​ Selling, general and administrative ​ 925 ​ 562 ​ 1,765 ​ 1,244 ​ Cost of goods sold ​ ​ 9 ​ ​ — ​ ​ 20 ​ ​ — ​ Total stock-based compensation ​ $ 1,182 ​ $ 766 ​ $ 2,293 ​ $ 1,657 ​ ​ Stock Options ​ A summary of stock option activity and related information through June 30, 2021 follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ Average ​ Contractual ​ ​ Number of ​ Exercise ​ Term ​ ​ Shares ​ Price ​ (in years) Balance, December 31, 2020 9,564,519 ​ $ 3.07 7.17 Granted 2,496,242 ​ 1.90 ​ ​ Exercised (137,184) ​ 1.31 ​ ​ Forfeited/Cancelled (127,818) ​ 3.02 ​ ​ Balance, June 30, 2021 11,795,759 ​ $ 2.85 7.28 Vested or expected to vest at June 30, 2021 11,795,759 ​ $ 2.85 7.28 Exercisable at June 30, 2021 6,662,268 ​ $ 3.57 5.87 ​ The aggregate intrinsic value of options exercisable as of June 30, 2021 was $1.2 million, based on the difference between the Company’s closing stock price of $1.69 and the exercise price of each stock option. At June 30, 2021, there was $6.7 million of total unrecognized compensation expense related to unvested options that will be recognized over the weighted average remaining vesting period of 3.16 years. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes model requires the Company to make certain estimates and assumptions, including estimating the fair value of the Company’s common stock, assumptions related to the expected price volatility of the Company’s common stock, the period during which the options will be outstanding, the rate of return on risk-free investments and the expected dividend yield for the Company’s common stock. The per-share weighted-average grant date fair value of the options granted to employees and directors during the six months ended June 30, 2021 and 2020 was estimated at $1.48 and $0.73 per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ ​ 2021 2020 Expected term of options (in years) 6.1 5.7 Risk-free interest rate 0.9 % 0.7 % Expected volatility 97.7 % 96.1 % Dividend yield — % — % ​ Restricted Stock Units RSU-related expense is recognized on a straight-line basis over the vesting period. Upon vesting, these awards may be settled on a net-exercise basis to cover any required withholding tax with the remaining amount converted into an equivalent number of shares of common stock. The following is a summary of changes in the status of non-vested RSUs during the year: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ ​ Awards ​ Fair Value Non-vested at December 31, 2020 3,771,342 ​ $ 1.66 Granted — ​ ​ — Vested (143,750) ​ ​ 0.85 Forfeited (124,560) ​ ​ 1.97 Non-vested at June 30, 2021 3,503,032 ​ $ 1.69 ​ For the six months ended June 30, 2021, the Company recorded $1.0 million in stock-based compensation expense related to RSUs, which is reflected in the statement of operations and comprehensive loss. As of June 30, 2021, there was $4.8 million of total unrecognized compensation expense related to unvested RSUs that will be recognized over the weighted average remaining period of 3.21 years. Shares Available for Future Grant At June 30, 2021, the Company has the following shares available to be granted under its equity incentive plans: ​ ​ ​ ​ ​ ​ ​ Inducement ​ ​ 2013 Plan ​ Plan Available at December 31, 2020 4,053,501 252,500 Authorized 6,399,997 ​ — Granted (2,496,242) ​ — Shares withheld for taxes not issued ​ 49,915 ​ — Forfeited/Cancelled 252,378 ​ — Available at June 30, 2021 8,259,549 252,500 ​ Shares Reserved for Future Issuance At June 30, 2021, the Company has reserved the following shares of common stock for issuance: ​ ​ ​ Stock options outstanding under 2013 Plan 11,548,259 Restricted stock units outstanding under 2013 Plan ​ 3,503,032 Shares reserved for future issuance under 2013 Plan 8,259,549 Stock options outstanding under Inducement Plan 247,500 Shares reserved for future issuance under Inducement Plan 252,500 Shares reserved for future issuance under 2013 Employee Stock Purchase Plan 225,806 Warrants outstanding 295,591 Total shares of common stock reserved for future issuance 24,332,237 ​

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies.
Commitments and Contingencies	6. Commitments and Contingencies Leases The Company leases office space in Chesterbrook, Pennsylvania and equipment. The Company’s principal office is located at 955 Chesterbrook Boulevard, Chesterbrook, Pennsylvania, where the Company currently leases approximately 8,231 square feet of developed office space on the first floor and 40,565 square feet of developed office space on the second floor. The lease term for this space extends through May 2028. On October 11, 2018, the Company entered into an agreement with The Vanguard Group, Inc., or Vanguard, whereby Vanguard agreed to sublease the 40,565 square feet of space on the second floor for an initial term of 37 months. On October 2, 2020, Vanguard notified the Company that they exercised the first option to extend the sublease term for three years through November 30, 2024. Vanguard has a second option to extend the sublease term for an additional three years through November 30, 2027. The sublease provides for rent abatement for the first month of the term; thereafter, the rent payable to the Company by Vanguard under the sublease is (i) $0.50 less during months 2 through 13 of the sublease and (ii) in month 14 and thereafter of the sublease, $1.00 less than the base rent payable by the Company under its master lease with Chesterbrook Partners, L.P. Vanguard also is responsible for paying to the Company all tenant energy costs, annual operating costs, and annual tax costs attributable to the subleased space during the term of the sublease. Rent expense and associated sublease income are recorded in the Company’s statements of operations and comprehensive loss as other income (expense). Supplemental balance sheet information related to leases was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 ​ Operating leases: ​ ​ ​ Operating lease right-of-use assets $ 4,921 $ 5,119 ​ Other current liabilities ​ ​ 741 ​ ​ 696 ​ Operating lease liabilities ​ ​ 6,717 ​ ​ 7,097 ​ Total operating lease liabilities ​ $ 7,458 ​ $ 7,793 ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance leases: ​ ​ ​ ​ ​ ​ ​ Property and equipment, at cost ​ $ 45 ​ $ 45 ​ Accumulated depreciation ​ ​ (38) ​ ​ (34) ​ Property and equipment, net ​ ​ 7 ​ ​ 11 ​ Other current liabilities ​ ​ 7 ​ ​ 7 ​ Other long-term liabilities ​ ​ 1 ​ ​ 4 ​ Total finance lease liabilities ​ $ 8 ​ $ 11 ​ ​ The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2021 2020 2021 2020 Operating lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease rental expense ​ $ 311 ​ $ 373 ​ $ 829 ​ $ 692 Other income ​ ​ (304) ​ ​ (301) ​ ​ (617) ​ ​ (601) Total operating lease costs ​ $ 7 ​ $ 72 ​ $ 212 ​ $ 91 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ ​ 2 ​ ​ 2 ​ ​ 4 ​ ​ 4 Interest on lease liabilities ​ ​ — ​ ​ — ​ ​ — ​ ​ — Total finance lease costs ​ $ 2 ​ $ 2 ​ $ 4 ​ $ 4 ​ Supplemental cash flow information related to leases was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, ​ 2021 2020 Cash paid for amounts included in the measurement of lease liabilities ​ ​ Operating cash flows from operating leases ​ $ (347) ​ $ (188) Operating cash flows from finance leases ​ — ​ — Financing cash flows from finance leases ​ ​ (4) ​ (5) ​ Our operating lease liabilities will mature, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Financing Leases 2021 (July 1 - December 31) ​ $ 693 ​ $ 4 2022 ​ ​ 1,401 ​ ​ 4 2023 ​ ​ 1,425 ​ ​ — 2024 ​ ​ 1,450 ​ ​ — 2025 ​ ​ 1,474 ​ ​ — 2026 and beyond ​ ​ 3,661 ​ ​ — Total minimum lease payments ​ $ 10,104 ​ $ 8 Interest Expense ​ ​ (2,646) ​ ​ - Lease liability ​ $ 7,458 ​ $ 8 ​ Per the terms of our sublease, we expect the following inflows (in thousands): ​ ​ ​ ​ ​ Sublease 2021 (July 1 - December 31) ​ $ 550 2022 ​ ​ 1,118 2023 ​ 1,139 2024 ​ ​ 996 2025 ​ — 2026 and beyond ​ — Total minimum lease payments ​ $ 3,803 ​ Lease term and discount rates are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 Weighted average remaining lease term (years) ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 7 ​ ​ 8 Finance leases ​ ​ 1 ​ ​ 1 Weighted average discount rate ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 9.2% ​ ​ 9.2% Finance leases ​ ​ 6.5% ​ ​ 6.5% ​ Legal Proceedings In October and November 2018, the Company and certain current and former officers and directors were sued in three purported class actions filed in the U.S. District Court for the Eastern District of Pennsylvania, or the EDPA, alleging violations of the federal securities laws. In January 2019, the three lawsuits were consolidated into one action, and on May 29, 2019, the District Court appointed a group of five individual investors as lead plaintiffs. A consolidated amended complaint was filed on August 2, 2019, alleging, among other things, that the Company and two former officers made false and misleading statements regarding the Company’s business, operations, and prospects, including certain statements made relating to the Company’s End-of-Phase 2 meeting with the FDA, and certain statements concerning top-line results from the Company’s Phase 3 studies. The plaintiffs seek, among other remedies, unspecified damages, attorneys’ fees and other costs, and unspecified equitable or injunctive relief. On August 28, 2020, the EDPA granted in part and denied in part the defendants’ motion to dismiss. On October 2, 2020, the Company and the individual defendants filed their answer to the amended complaint, denying all liability. On February 11, 2021, the parties agreed in principle to a settlement, which is subject to approval by the Court, and the Court issued its preliminary approval of the settlement on May 3, 2021 and finally approved the settlement on August 2, 2021. The Company and the individual defendants do not acknowledge any wrongdoing as part of the settlement, and a monetary payment of $8.5 million will be made to the plaintiffs and their counsel, all of which will be funded by the Company’s insurance carriers. The Company has recorded the $8.5 million estimated settlement liability and the $8.5 million estimated insurance recovery in its 2020 financial statements. The Company continues to believe that the claims are without merit, and if necessary, the Company intends to vigorously defend itself and its former officers against the allegations. In December 2018, a shareholder derivative action was filed on behalf of the Company and against certain current and former officers and directors in the EDPA, and in February 2019, two additional, similar shareholder derivative actions were filed in the U.S. District Court for the District of Delaware. A fourth similar shareholder derivative action was filed in the EDPA in September 2019, and a fifth, similar derivative action was filed in the EDPA in November 2019. A similar sixth derivative action was filed in the EDPA in September 2020. These cases, which involve facts similar to the consolidated securities lawsuits, assert claims against the individual defendants for, among other things, breach of fiduciary duty, waste of corporate assets, violations of the federal securities laws, and unjust enrichment, and they make a number of demands, including for monetary damages and other equitable and injunctive relief. The parties agreed to a settlement, which was preliminarily approved by the Court on May 27, 2021, and finally approved by the Court on August 2, 2021. The individual defendants do not acknowledge any wrongdoing as part of the settlement. The Company has agreed to make certain corporate governance changes, and a monetary payment of $500,000 will be made to plaintiffs’ counsel, all of which will be funded by the Company’s insurance carriers. The Company recorded in the fourth quarter of 2020

Product Revenue

Product Revenue	6 Months Ended
	Jun. 30, 2021
Product Revenue
Product Revenue	7. Product Revenue ​ Performance Obligation The Company’s performance obligation is the supply of finished pharmaceutical products to its customers. The Company’s customers consist of major wholesale distributors. The Company’s customer contracts generally consist of both a master agreement, which is signed by the Company and its customer, and a customer submitted purchase order, which is governed by the terms and conditions of the master agreement. Revenue is recognized when the Company transfers control of its products to the customer, which occurs at a point-in-time, upon delivery. The Company offers standard payment terms to its customers and has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing, since the period between when the Company transfers the product to the customer and when the customer pays for that product is one year or less. Taxes collected from customers relating to product revenue and remitted to governmental authorities are excluded from revenues. The consideration amounts due from customers as a result of product revenue are subject to variable consideration. The Company offers standard product warranties which provide assurance that the product will function as expected and in accordance with specifications. Customers cannot purchase warranties separately and these warranties do not give rise to a separate performance obligation. The Company permits the return of product under certain circumstances, mainly upon at or near product expiration, instances of shipping errors or where product is damaged in transit. The Company accrues for the customer’s right to return as part of its variable consideration. Concentration of Revenue Two of the Company’s largest customers account for 100% of total product revenue for the six months ended June 30, 2021. The following table presents a rollforward of the major categories of sales-related deductions included in trade receivable allowances for the six months ended June 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sales Discounts Chargebacks Fee for Service Balance, January 1, 2021 ​ $ 2 ​ $ 5 ​ $ 10 Provision related to current period sales ​ ​ 19 ​ ​ 28 ​ ​ 59 Adjustment related to prior period sales ​ — ​ ​ — ​ ​ — Credit or payments made during the period ​ ​ (7) ​ ​ — ​ ​ (6) Balance, June 30, 2021 ​ $ 14 ​ $ 33 ​ $ 63 ​

License Revenue

License Revenue	6 Months Ended
	Jun. 30, 2021
License Revenue
License Revenue	8. License Revenue ​ License and Commercialization Agreement with Pharmbio Korea Inc. In April 2018, the Company entered into an exclusive license agreement with Pharmbio Korea Inc., or Pharmbio, for the development and commercialization of OLINVYK for the management of moderate-to-severe acute pain in South Korea. Under the terms of the agreement, the Company received an upfront, non-refundable cash payment of $3.0 million (less applicable withholding taxes of $0.5 million) in June 2018, and will receive a cash commercial milestone of up to $0.5 million if OLINVYK is approved in South Korea and tiered royalties on product sales in South Korea ranging from high single digits to 20%, less applicable withholding taxes. As part of the agreement, the Company also granted Pharmbio an option to manufacture OLINVYK, on a non-exclusive basis, for the development and commercialization of the product in South Korea, subject to a separate arrangement to be entered into if Pharmbio exercises the option. The license agreement is terminable by Pharmbio for any reason upon 180 days written notice. In accordance with the terms of the agreement, Pharmbio is solely responsible for all development and regulatory activities in South Korea. The parties have formed a Joint Development Committee with equal representation from the Company and Pharmbio to provide overall coordination and oversight of the development of OLINVYK in South Korea. The parties also agreed to form a Joint Manufacturing and Commercialization Committee at least six months prior to the anticipated date of regulatory approval of OLINVYK in South Korea to provide overall coordination and oversight of the manufacture and commercialization of OLINVYK in South Korea. License Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. In April 2018, the Company also entered into an exclusive license agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd., or Nhwa, for the development and commercialization of OLINVYK for the management of moderate-to-severe acute pain in China. Under the terms of this agreement, the Company received an upfront, non-refundable cash payment of $2.5 million (less applicable withholding taxes of $0.3 million) in July 2018. In August 2020, the Company received a milestone payment of $3.0 million (less applicable withholding taxes of $0.3 million), that became payable by Nhwa upon FDA approval of OLINVYK. The Company is also eligible to receive a cash milestone payment of $3.0 million, subject to Chinese withholding taxes, upon regulatory approval of OLINVYK in China, up to an additional $6.0 million of commercialization milestone payments based on product sales levels in China, and a ten percent royalty on all net product sales in China, less applicable withholding taxes. As part of the agreement, the Company also granted Nhwa an option to manufacture OLINVYK, on an exclusive basis in China, for the development and commercialization of the product in China. In the second quarter of 2018, Nhwa elected to exercise this manufacturing option. The license agreement is terminable by Nhwa for any reason upon 180 days written notice. In accordance with the terms of the agreement, Nhwa is solely responsible for all development and regulatory activities in China. The parties have formed a Joint Development Committee with equal representation from the Company and Nhwa to provide overall coordination and oversight of the development of OLINVYK in China. The parties also agreed to form a Joint Manufacturing and Commercialization Committee at least six months prior to the anticipated date of regulatory approval of OLINVYK in China to provide overall coordination and oversight of the manufacture and commercialization of OLINVYK in China.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2021
Net Loss Per Common Share
Net Loss Per Common Share	9. Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Basic and diluted net loss per common share calculation: ​ ​ ​ ​ Net loss ​ $ (14,022) ​ $ (6,222) ​ $ (23,864) ​ $ (11,947) ​ Weighted average common shares outstanding ​ 163,370,485 ​ 111,297,428 ​ 161,936,680 ​ 103,814,876 ​ Net loss per share of common stock - basic and diluted ​ $ (0.09) ​ $ (0.06) ​ $ (0.15) ​ $ (0.12) ​ ​ The following outstanding securities at June 30, 2021 and 2020 have been excluded from the computation of diluted weighted shares outstanding, as they would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2021 2020 Options outstanding 11,795,759 8,046,378 RSUs outstanding ​ 3,503,032 ​ 3,008,435 ​ Warrants 295,591 623,091 Total 15,594,382 11,677,904 ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the ASC and Accounting Standards Update, or ASU, of FASB. The Company’s functional currency is the U.S. dollar. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s balance sheets as of June 30, 2021, its results of operations and its comprehensive loss for the three and six months ended June 30, 2021 and 2020, its statement of stockholders’ equity for the period from January 1, 2021 to June 30, 2021 and for the period January 1, 2020 to June 30, 2020, and its statements of cash flows for the six months ended June 30, 2021 and 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and accompanying notes included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2020. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies. The financial data and other information disclosed in these notes related to the six months ended June 30, 2021 and 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. We have been actively monitoring the novel coronavirus, or COVID-19, situation and its impact globally. Remote working arrangements and travel restrictions imposed by various jurisdictions have had a limited impact on our ability to maintain operations during the quarter. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, including vaccine adoption and effectiveness, the impact of emerging variants of the novel coronavirus, the actions taken to contain or treat COVID-19, including as a result of new information that may emerge concerning COVID-19.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. These estimates and assumptions are based on current facts, historical experience as well as other pertinent industry and regulatory authority information, including the potential future effects of COVID-19, the results of which form the basis for making judgements about the carrying values of assets and liabilities and the recording expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value of Financial Instruments
Schedule of cash, cash equivalents and marketable securities	The following table presents fair value of the Company’s cash, cash equivalents, and marketable securities as of June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ Adjusted ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cash and Cash ​ Restricted ​ Marketable ​ ​ Cost Gains Losses Fair Value Equivalents Cash Securities Cash ​ $ 10,557 ​ $ — ​ $ — ​ $ 10,557 ​ $ 9,247 ​ $ 1,310 ​ $ — Level 1 (1): ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 81,705 ​ — ​ — ​ 81,705 ​ 81,705 ​ — ​ — Subtotal ​ 81,705 ​ — ​ — ​ 81,705 ​ 81,705 ​ — ​ — Total ​ $ 92,262 ​ $ — ​ $ — ​ $ 92,262 ​ $ 90,952 ​ $ 1,310 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ Adjusted ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cash and Cash ​ Restricted ​ Marketable ​ Cost Gains Losses Fair Value Equivalents Cash Securities Cash ​ $ 6,100 ​ $ — ​ $ — ​ $ 6,100 ​ $ 4,790 ​ $ 1,310 ​ $ — Level 1 (1): ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 104,613 ​ — ​ — ​ 104,613 ​ 104,613 ​ — ​ — Subtotal ​ 104,613 ​ — ​ — ​ 104,613 ​ 104,613 ​ — ​ — Total ​ $ 110,713 ​ $ — ​ $ — ​ $ 110,713 ​ $ 109,403 ​ $ 1,310 ​ $ — (1) The fair value of Level 1 securities is estimated based on quoted prices in active markets for identical assets or liabilities.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity
Schedule of share-based compensation expense recognized	The estimated grant-date fair value of the Company’s stock-based awards is amortized on a straight-line basis over the awards’ service periods. Stock-based compensation expense recognized was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Research and development ​ $ 248 ​ $ 204 ​ $ 508 ​ $ 413 ​ Selling, general and administrative ​ 925 ​ 562 ​ 1,765 ​ 1,244 ​ Cost of goods sold ​ ​ 9 ​ ​ — ​ ​ 20 ​ ​ — ​ Total stock-based compensation ​ $ 1,182 ​ $ 766 ​ $ 2,293 ​ $ 1,657 ​
Summary of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ Average ​ Contractual ​ ​ Number of ​ Exercise ​ Term ​ ​ Shares ​ Price ​ (in years) Balance, December 31, 2020 9,564,519 ​ $ 3.07 7.17 Granted 2,496,242 ​ 1.90 ​ ​ Exercised (137,184) ​ 1.31 ​ ​ Forfeited/Cancelled (127,818) ​ 3.02 ​ ​ Balance, June 30, 2021 11,795,759 ​ $ 2.85 7.28 Vested or expected to vest at June 30, 2021 11,795,759 ​ $ 2.85 7.28 Exercisable at June 30, 2021 6,662,268 ​ $ 3.57 5.87
Schedule of weighted-average assumptions:	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ ​ 2021 2020 Expected term of options (in years) 6.1 5.7 Risk-free interest rate 0.9 % 0.7 % Expected volatility 97.7 % 96.1 % Dividend yield — % — %
Schedule of changes in the status of non-vested RSU	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ ​ Awards ​ Fair Value Non-vested at December 31, 2020 3,771,342 ​ $ 1.66 Granted — ​ ​ — Vested (143,750) ​ ​ 0.85 Forfeited (124,560) ​ ​ 1.97 Non-vested at June 30, 2021 3,503,032 ​ $ 1.69
Schedule of shares available to be granted under equity incentive plans	At June 30, 2021, the Company has the following shares available to be granted under its equity incentive plans: ​ ​ ​ ​ ​ ​ ​ Inducement ​ ​ 2013 Plan ​ Plan Available at December 31, 2020 4,053,501 252,500 Authorized 6,399,997 ​ — Granted (2,496,242) ​ — Shares withheld for taxes not issued ​ 49,915 ​ — Forfeited/Cancelled 252,378 ​ — Available at June 30, 2021 8,259,549 252,500
Schedule of shares of common stock reserved/available	At June 30, 2021, the Company has reserved the following shares of common stock for issuance: ​ ​ ​ Stock options outstanding under 2013 Plan 11,548,259 Restricted stock units outstanding under 2013 Plan ​ 3,503,032 Shares reserved for future issuance under 2013 Plan 8,259,549 Stock options outstanding under Inducement Plan 247,500 Shares reserved for future issuance under Inducement Plan 252,500 Shares reserved for future issuance under 2013 Employee Stock Purchase Plan 225,806 Warrants outstanding 295,591 Total shares of common stock reserved for future issuance 24,332,237

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies.
Schedule of balance sheet information related to leases	Supplemental balance sheet information related to leases was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 ​ Operating leases: ​ ​ ​ Operating lease right-of-use assets $ 4,921 $ 5,119 ​ Other current liabilities ​ ​ 741 ​ ​ 696 ​ Operating lease liabilities ​ ​ 6,717 ​ ​ 7,097 ​ Total operating lease liabilities ​ $ 7,458 ​ $ 7,793 ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance leases: ​ ​ ​ ​ ​ ​ ​ Property and equipment, at cost ​ $ 45 ​ $ 45 ​ Accumulated depreciation ​ ​ (38) ​ ​ (34) ​ Property and equipment, net ​ ​ 7 ​ ​ 11 ​ Other current liabilities ​ ​ 7 ​ ​ 7 ​ Other long-term liabilities ​ ​ 1 ​ ​ 4 ​ Total finance lease liabilities ​ $ 8 ​ $ 11 ​ ​
Schedule of components of lease expense	The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2021 2020 2021 2020 Operating lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease rental expense ​ $ 311 ​ $ 373 ​ $ 829 ​ $ 692 Other income ​ ​ (304) ​ ​ (301) ​ ​ (617) ​ ​ (601) Total operating lease costs ​ $ 7 ​ $ 72 ​ $ 212 ​ $ 91 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ ​ 2 ​ ​ 2 ​ ​ 4 ​ ​ 4 Interest on lease liabilities ​ ​ — ​ ​ — ​ ​ — ​ ​ — Total finance lease costs ​ $ 2 ​ $ 2 ​ $ 4 ​ $ 4 ​
Schedule of supplemental cash flow information	Supplemental cash flow information related to leases was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, ​ 2021 2020 Cash paid for amounts included in the measurement of lease liabilities ​ ​ Operating cash flows from operating leases ​ $ (347) ​ $ (188) Operating cash flows from finance leases ​ — ​ — Financing cash flows from finance leases ​ ​ (4) ​ (5) ​
Schedule of maturities of operating lease liabilities	Our operating lease liabilities will mature, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Financing Leases 2021 (July 1 - December 31) ​ $ 693 ​ $ 4 2022 ​ ​ 1,401 ​ ​ 4 2023 ​ ​ 1,425 ​ ​ — 2024 ​ ​ 1,450 ​ ​ — 2025 ​ ​ 1,474 ​ ​ — 2026 and beyond ​ ​ 3,661 ​ ​ — Total minimum lease payments ​ $ 10,104 ​ $ 8 Interest Expense ​ ​ (2,646) ​ ​ - Lease liability ​ $ 7,458 ​ $ 8
Schedule of maturities of financing lease liabilities	Our operating lease liabilities will mature, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Financing Leases 2021 (July 1 - December 31) ​ $ 693 ​ $ 4 2022 ​ ​ 1,401 ​ ​ 4 2023 ​ ​ 1,425 ​ ​ — 2024 ​ ​ 1,450 ​ ​ — 2025 ​ ​ 1,474 ​ ​ — 2026 and beyond ​ ​ 3,661 ​ ​ — Total minimum lease payments ​ $ 10,104 ​ $ 8 Interest Expense ​ ​ (2,646) ​ ​ - Lease liability ​ $ 7,458 ​ $ 8
Schedule of expected sublease inflows	Per the terms of our sublease, we expect the following inflows (in thousands): ​ ​ ​ ​ ​ Sublease 2021 (July 1 - December 31) ​ $ 550 2022 ​ ​ 1,118 2023 ​ 1,139 2024 ​ ​ 996 2025 ​ — 2026 and beyond ​ — Total minimum lease payments ​ $ 3,803 ​
Schedule of weighted average lease term and discount rates	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 2020 Weighted average remaining lease term (years) ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 7 ​ ​ 8 Finance leases ​ ​ 1 ​ ​ 1 Weighted average discount rate ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 9.2% ​ ​ 9.2% Finance leases ​ ​ 6.5% ​ ​ 6.5%

Product Revenue (Tables)

Product Revenue (Tables)	6 Months Ended
	Jun. 30, 2021
Product Revenue
Schedule of major categories of sales-related deductions included in trade receivable allowances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sales Discounts Chargebacks Fee for Service Balance, January 1, 2021 ​ $ 2 ​ $ 5 ​ $ 10 Provision related to current period sales ​ ​ 19 ​ ​ 28 ​ ​ 59 Adjustment related to prior period sales ​ — ​ ​ — ​ ​ — Credit or payments made during the period ​ ​ (7) ​ ​ — ​ ​ (6) Balance, June 30, 2021 ​ $ 14 ​ $ 33 ​ $ 63

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2021
Net Loss Per Common Share
Schedule of computation of basic and diluted net loss per share	The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Basic and diluted net loss per common share calculation: ​ ​ ​ ​ Net loss ​ $ (14,022) ​ $ (6,222) ​ $ (23,864) ​ $ (11,947) ​ Weighted average common shares outstanding ​ 163,370,485 ​ 111,297,428 ​ 161,936,680 ​ 103,814,876 ​ Net loss per share of common stock - basic and diluted ​ $ (0.09) ​ $ (0.06) ​ $ (0.15) ​ $ (0.12) ​ ​
Schedule of outstanding securities excluded from the computation of diluted weighted shares outstanding as they would have been anti-dilutive	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2021 2020 Options outstanding 11,795,759 8,046,378 RSUs outstanding ​ 3,503,032 ​ 3,008,435 ​ Warrants 295,591 623,091 Total 15,594,382 11,677,904

Organization and Description _2

Organization and Description of the Business (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Organization and Description of the Business
Number of operating segments					1
Accumulated deficit	$ 466,378,000				$ 466,378,000		$ 442,514,000
Net loss	$ 14,022,000	$ 9,842,000	$ 6,222,000	$ 5,725,000	$ 23,864,000	$ 11,947,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair value
Transfers between Level 2 and Level 3	$ 0	$ 0
Letter of credit collateral	1,300
Adjusted cost
Fair value
Cash and Cash Equivalents, Fair Value Disclosure	10,557	6,100
Assets, Fair Value Disclosure	92,262	110,713
Fair Value
Fair value
Cash and Cash Equivalents, Fair Value Disclosure	10,557	6,100
Assets, Fair Value Disclosure	92,262	110,713
Cash and Cash Equivalents | Fair Value
Fair value
Cash and Cash Equivalents, Fair Value Disclosure	9,247	4,790
Assets, Fair Value Disclosure	90,952	109,403
Restricted Cash | Fair Value
Fair value
Cash and Cash Equivalents, Fair Value Disclosure	1,310	1,310
Assets, Fair Value Disclosure	1,310	1,310
Level 1 | Adjusted cost
Fair value
Investments, Fair Value Disclosure	81,705	104,613
Level 1 | Fair Value
Fair value
Investments, Fair Value Disclosure	81,705	104,613
Level 1 | Money market funds | Adjusted cost
Fair value
Investments, Fair Value Disclosure	81,705	104,613
Level 1 | Money market funds | Fair Value
Fair value
Investments, Fair Value Disclosure	81,705	104,613
Level 1 | Cash and Cash Equivalents | Fair Value
Fair value
Investments, Fair Value Disclosure	81,705	104,613
Level 1 | Cash and Cash Equivalents | Money market funds | Fair Value
Fair value
Investments, Fair Value Disclosure	$ 81,705	$ 104,613

Stockholders' Equity - Equity O

Stockholders' Equity - Equity Offerings (Details)	Jan. 29, 2019USD ($)Institution$ / sharesshares	Jan. 28, 2019USD ($)$ / sharesshares	May 10, 2020USD ($)shares	Jun. 30, 2021USD ($)shares	Jun. 30, 2021USD ($)shares	Mar. 31, 2021USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2021USD ($)shares	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)shares	Apr. 17, 2019USD ($)
Stockholders' Equity
Common stock authorized (in shares) | shares				200,000,000	200,000,000				200,000,000		200,000,000
Preferred stock authorized (in shares) | shares				5,000,000	5,000,000				5,000,000		5,000,000
Net proceeds from the offering									$ 7,948,000	$ 35,580,000
Issuance of common stock, net of issuance costs					$ 5,156,000	$ 2,792,000	$ 32,029,000	$ 3,551,000
Wainwright
Stockholders' Equity
Percentage of aggregate gross proceeds paid		7.00%
Expenses paid		$ 50,000
Warrants to purchase shares of common stock | shares		500,000
Warrants term		5 years
Exercise price (in dollars per share) | $ / shares		$ 1.25
Number of warrants exercised in a cashless exercise | shares											327,500
Common shares issued in conversion of warrants | shares											201,925
At-the-market sales facility - April 17, 2019 agreement | Wainwright | Maximum
Stockholders' Equity
Offering amount												$ 50,000,000
At-the-market sales facility - December 31, 2020 agreement | Wainwright
Stockholders' Equity
Offering amount											$ 50,000,000
Private Placement
Stockholders' Equity
Issuance of common stock (in shares) | shares	10,000,000
Offering price (in dollars per share) | $ / shares	$ 1
Issuance of common stock, net of issuance costs	$ 9,200,000
Number of institutional investors | Institution	2
HCW ATM Program
Stockholders' Equity
Issuance of common stock (in shares) | shares			3,100,000	0					4,300,000
Net proceeds from the offering			$ 5,200,000						$ 8,100,000
Stock available for further issuance				$ 41,900,000	$ 41,900,000				$ 41,900,000

Stockholders' Equity - Equity I

Stockholders' Equity - Equity Incentive Plans (Details) - USD ($) $ in Thousands	Dec. 15, 2016	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Equity Incentive Plans
Stock-based compensation		$ 1,182	$ 766	$ 2,293	$ 1,657
Research and evelopment
Equity Incentive Plans
Stock-based compensation		248	204	508	413
Selling, general and administrative
Equity Incentive Plans
Stock-based compensation		925	$ 562	1,765	$ 1,244
Cost of goods sold
Equity Incentive Plans
Stock-based compensation		$ 9		$ 20
2008 Plan and 2013 Plan
Equity Incentive Plans
Authorized (in shares)	500,000
2008 Plan and 2013 Plan | Maximum
Equity Incentive Plans
Term of award				10 years
Vesting period				4 years

Stockholders' Equity - Options

Stockholders' Equity - Options Outstanding (Details) $ / shares in Units, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares
Number of Shares
Balance at the beginning of the period (in shares) | shares	9,564,519
Granted (in shares) | shares	2,496,242
Exercised (in shares) | shares	(137,184)
Forfeited/Cancelled (in shares) | shares	(127,818)
Balance at the end of the period (in shares) | shares	11,795,759	9,564,519
Vested or expected to vest at the end of the period (in shares) | shares	11,795,759
Exercisable at the end of the period (in shares) | shares	6,662,268
Weighted-Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 3.07
Granted (in dollars per share)	1.90
Exercised (in dollars per share)	1.31
Forfeited/Cancelled (in dollars per share)	(3.02)
Balance at the end of the period (in dollars per share)	2.85	$ 3.07
Vested or expected to vest at the end of the period (in dollars per share)	2.85
Exercisable at the end of the period (in dollars per share)	$ 3.57
Intrinsic value of options exercisable | $	$ 1.2
Closing price of Company's stock (in dollars per share)	$ 1.69
Weighted Average Remaining Contractual Term
Options Outstanding at the end of the period	7 years 3 months 10 days	7 years 2 months 1 day
Vested or expected to vest at the end of the period	7 years 3 months 10 days
Exercisable at the end of the period	5 years 10 months 13 days

Stockholders' Equity - Option_2

Stockholders' Equity - Options Other Info (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Options outstanding
Intrinsic value of options exercisable	$ 1.2
Closing price of Company's stock (in dollars per share)	$ 1.69
Employee Stock Option
Options outstanding
Unrecognized compensation expense	$ 6.7
Weighted average remaining period for recognition of unrecognized compensation expense	3 years 1 month 28 days
Per-share weighted-average grant date fair value of options granted (in dollars per share)	$ 1.48	$ 0.73
Employee Stock Option | Weighted-average
Weighted-average assumptions:
Expected term of options (in years)	6 years 1 month 6 days	5 years 8 months 12 days
Risk-free interest rate (as a percent)	0.90%	0.70%
Expected volatility (as a percent)	97.70%	96.10%

Stockholders' Equity - Non-vest

Stockholders' Equity - Non-vested RSUs (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Weighted Average Grant Date Fair Value
Stock-based compensation	$ 1,182	$ 766	$ 2,293	$ 1,657
Restricted Stock Units
Number of Shares
Non-vested at beginning of period (in shares)			3,771,342
Vested (in shares)			(143,750)
Forfeited/Cancelled			(124,560)
Non-vested at end of period (in shares)	3,503,032		3,503,032
Weighted Average Grant Date Fair Value
Non-vested at beginning of period (in dollars per share)			$ 1.66
Vested (in dollars per share)			0.85
Forfeited (in dollars per share)			1.97
Non-vested at end of period (in dollars per share)	$ 1.69		$ 1.69
Stock-based compensation			$ 1,000
Unrecognized compensation expense	$ 4,800		$ 4,800
Weighted average remaining period for recognition of unrecognized compensation expense			3 years 2 months 15 days

Stockholder's Equity - Shares R

Stockholder's Equity - Shares Reserved for Future Grant and Issuance (Details) - shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Shares Reserved for Future Issuance
Stock options outstanding (in shares)	11,795,759	9,564,519
Warrants outstanding (in shares)	295,591
Total shares of common stock reserved for issuance (in shares)	24,332,237
2013 plan
Shares Available for Future Grant
Balance at the beginning of the period (in shares)	4,053,501
Authorized (in shares)	6,399,997
Granted (in shares)	(2,496,242)
Shares withheld for taxes not issued	49,915
Forfeited/Cancelled (in shares)	252,378
Balance at the end of the period (in shares)	8,259,549
Shares Reserved for Future Issuance
Shares available for future grant (in shares)	8,259,549	4,053,501
Inducement Plan
Shares Available for Future Grant
Balance at the beginning of the period (in shares)	252,500
Balance at the end of the period (in shares)	252,500
Shares Reserved for Future Issuance
Shares available for future grant (in shares)	252,500	252,500
2013 Employee Stock Purchase Plan
Shares Reserved for Future Issuance
Total shares of common stock reserved for issuance (in shares)	225,806
Employee Stock Option | 2013 plan
Shares Reserved for Future Issuance
Stock options outstanding (in shares)	11,548,259
Employee Stock Option | Inducement Plan
Shares Reserved for Future Issuance
Stock options outstanding (in shares)	247,500
Restricted Stock Units | 2013 plan
Shares Reserved for Future Issuance
Total shares of common stock reserved for issuance (in shares)	3,503,032

Commitments and Contingencies -

Commitments and Contingencies - Leases (Details) - Chesterbrook, Pennsylvania	Oct. 02, 2020	Oct. 11, 2018ft²	Jun. 30, 2021ft²$ / ft²
Leases
Number of square feet of space leased on the first floor			8,231
Number of square feet of space leased on the second floor			40,565
Sublease Agreements | Vanguard Group, Inc
Leases
Number of square feet of space being subleased on second floor		40,565
Initial term of sublease		37 months
Term of optional sublease extension	3 years
Term of second optional sublease extension			3 years
Amount per square foot less for rent during months 2 to 13 | $ / ft²			0.50
Amount per square foot for rent after month 14 | $ / ft²			1

Commitments and Contingencies_2

Commitments and Contingencies - Balance sheet information related to leases (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases
Operating lease right-of-use assets	$ 4,921	$ 5,119
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Operating lease right-of-use assets	Operating lease right-of-use assets
Operating lease liabilities - Current	$ 741	$ 696
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent	us-gaap:OtherLiabilitiesCurrent
Operating lease liabilities - Noncurrent	$ 6,717	$ 7,097
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Operating lease liabilities - Noncurrent	Operating lease liabilities - Noncurrent
Lease Liability	$ 7,458	$ 7,793
Operating Lease, Liability, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent us-gaap:OperatingLeaseLiabilityNoncurrent	us-gaap:OtherLiabilitiesCurrent us-gaap:OperatingLeaseLiabilityNoncurrent
Property and equipment, net	$ 2,039	$ 2,253
Finance lease liabilities - Current	$ 7	$ 7
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent	us-gaap:OtherLiabilitiesCurrent
Finance lease liabilities - Noncurrent	$ 1	$ 4
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesNoncurrent	us-gaap:OtherLiabilitiesNoncurrent
Lease Liability	$ 8	$ 11
Finance Lease, Liability, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent	us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent
Finance leased assets
Leases
Property and equipment, at cost	$ 45	$ 45
Accumulated depreciation	(38)	(34)
Property and equipment, net	$ 7	$ 11

Commitments and Contingencies_3

Commitments and Contingencies - Components of lease expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating lease costs:
Operating lease rental expense	$ 311	$ 373	$ 829	$ 692
Other income	(304)	(301)	(617)	(601)
Total operating lease costs	7	72	212	91
Finance lease costs:
Amortization of right-of-use assets	2	2	4	4
Total finance lease costs	$ 2	$ 2	$ 4	$ 4

Commitments and Contingencies_4

Commitments and Contingencies - Cash flow information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Commitments and Contingencies.
Operating cash flows from operating leases	$ (347)	$ (188)
Financing cash flows from finance leases	$ (4)	$ (5)

Commitments and Contingencies_5

Commitments and Contingencies - Lease liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Operating Leases
2021 (July 1 - December 31)	$ 693
2022	1,401
2023	1,425
2024	1,450
2025	1,474
2026 and beyond	3,661
Total minimum lease payments	10,104
Interest Expense	(2,646)
Lease Liability	7,458	$ 7,793
Financing Leases
2021 (July 1 - December 31)	4
2022	4
Total minimum lease payments	8
Lease Liability	8	$ 11
Sublease
2021 (July 1 - December 31)	550
2022	1,118
2023	1,139
2024	996
Total minimum lease payments	$ 3,803

Commitments and Contingencies_6

Commitments and Contingencies - Lease term and discount rates (Details)	Jun. 30, 2021	Jun. 30, 2020
Commitments and Contingencies.
Weighted average remaining lease term - Operating leases	7 years	8 years
Weighted average remaining lease term - Finance leases	1 year	1 year
Weighted average discount rate - Operating leases	9.20%	9.20%
Weighted average discount rate - Finance leases	6.50%	6.50%

Commitments and Contingencies_7

Commitments and Contingencies - Legal Proceedings (Details)	Feb. 11, 2021USD ($)	Aug. 02, 2019employee	May 29, 2019item	Feb. 28, 2019lawsuit	Jan. 31, 2019lawsuit	Nov. 30, 2018lawsuit	Dec. 31, 2020USD ($)	Jun. 30, 2021USD ($)
Legal Proceedings
Estimated settlement liability							$ 9,000,000	$ 9,000,000
Insurance recovery							9,000,000	$ 9,000,000
Class Actions In Eastern District Of Pennsylvania | Pending Litigation
Legal Proceedings
Number of claims | lawsuit						3
Number of claims after consolidation | lawsuit					1
Number of investors appointed | item			5
Number of former officers | employee		2
Estimated settlement liability							8,500,000
Insurance recovery							8,500,000
Class Actions In Eastern District Of Pennsylvania | Settled Litigation
Legal Proceedings
Monetary payment to be made to the plaintiff	$ 8,500,000
Shareholder Derivative Actions | Pending Litigation
Legal Proceedings
Number of claims | lawsuit				2
Monetary payment to be made to the plaintiff							500,000
Estimated settlement liability							500,000
Insurance recovery							$ 500,000

Product Revenue (Details)

Product Revenue (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)customer
Sales Discounts
Balance	$ 2
Provision related to current period sales	19
Credit or payments made during the period	(7)
Balance	14
Chargebacks
Balance	5
Provision related to current period sales	28
Balance	33
Fee for Service
Balance	10
Provision related to current period sales	59
Credit or payments made during the period	(6)
Balance	$ 63
Product revenue | Revenue Benchmark | Customer Concentration Risk
Revenue
Number of customers | customer	2
Concentration risk percentage	100.00%

License Revenue (Details)

License Revenue (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended	6 Months Ended
	Aug. 31, 2020	Jul. 31, 2018	Jun. 30, 2018	Jun. 30, 2021	Jun. 30, 2021
Licensing Arrangements
Total revenue				$ 178	$ 387
Pharmbio Korea Inc | Licensing agreements
Licensing Arrangements
Upfront payment			$ 3,000
Commercialization milestone payments			500
Withholding taxes			$ 500
Time period for written notice to terminate license agreement			180 days
Pharmbio Korea Inc | Licensing agreements | Minimum
Licensing Arrangements
Time period to form a committee prior to the anticipated date of regulatory approval			6 months
Pharmbio Korea Inc | Licensing agreements | Maximum
Licensing Arrangements
Royalties on product sales, percentage			20.00%
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements
Licensing Arrangements
Upfront payment		$ 2,500
Commercialization milestone payments	$ 3,000
Withholding taxes	300	$ 300
Milestone payment upon regulatory approval	3,000
Milestone payment upon sales targets reached in China	$ 6,000
Royalty percentage on net product sales in China after milestones met	10.00%
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements | Minimum
Licensing Arrangements
Time period to form a committee prior to the anticipated date of regulatory approval	6 months
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements | Maximum
Licensing Arrangements
Time period for written notice to terminate license agreement	180 days

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Basic and diluted net loss per common share calculation:
Net loss	$ (14,022)	$ (9,842)	$ (6,222)	$ (5,725)	$ (23,864)	$ (11,947)
Weighted average common shares outstanding (in shares)	163,370,485		111,297,428		161,936,680	103,814,876
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.09)		$ (0.06)		$ (0.15)	$ (0.12)
Outstanding securities excluded from computation of diluted weighted shares outstanding (in shares)					15,594,382	11,677,904
Employee Stock Option
Basic and diluted net loss per common share calculation:
Outstanding securities excluded from computation of diluted weighted shares outstanding (in shares)					11,795,759	8,046,378
Restricted Stock Units
Basic and diluted net loss per common share calculation:
Outstanding securities excluded from computation of diluted weighted shares outstanding (in shares)					3,503,032	3,008,435
Warrants
Basic and diluted net loss per common share calculation:
Outstanding securities excluded from computation of diluted weighted shares outstanding (in shares)					295,591	623,091